StreetInsider.com News Articles

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

Tue, 20 Oct 2026 08:00:00 -0400

CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

Tue, 20 Oct 2026 08:00:00 -0400

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 15 Oct 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 15 Oct 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new

Madrigal Pharmaceuticals (MDGL) PT Raised to $735 at UBS

Wed, 14 Oct 2026 06:49:32 -0400

UBS analyst Ashwani Verma raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $735.00 (from $669.00) while maintaining a Buy rating.

The analyst comments "Based on our analysis of the F4 Outcomes trial and higher likelihood of success, we are raising our PT to $735 (prior $669). We now assign a 60% PoS to the F4 program, up from 20% previously."

Madrigal Pharmaceuticals (MDGL) PT Raised to $735 at UBS

Wed, 14 Oct 2026 06:49:32 -0400

UBS analyst Ashwani Verma raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $735.00 (from $669.00) while maintaining a Buy rating.

Madrigal publishes Rezdiffra genetic subgroup data in liver journal

Tue, 06 Oct 2026 08:05:13 -0400

Madrigal Pharmaceuticals (NASDAQ: MDGL) announced the publication of a secondary analysis from its Phase 3 MAESTRO-NASH trial in the Journal of Hepatology, examining whether common genetic variants associated with metabolic dysfunction-associated steatohepatitis (MASH) affected patient response to Rezdiffra (resmetirom).

The analysis included 738 patients who consented to genetic testing and completed baseline and Week 52 liver biopsies. Across all major efficacy endpoints, including MASH resolution, fibrosis improvement, MRI-PDFF reduction and multiple biomarkers, the publication reports no meaningful difference in treatment response based on MASH genetic risk variants, including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7, or a composite genetic risk score.

In the

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Tue, 06 Oct 2026 08:00:00 -0400

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression

CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).

The analysis demonstrated that treatment with Rezdiffra resulted in

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Tue, 06 Oct 2026 08:00:00 -0400

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression

The analysis demonstrated that treatment with Rezdiffra resulted in

Goldman Sachs Assumes Madrigal Pharmaceuticals (MDGL) at Buy

Thu, 24 Sep 2026 05:37:21 -0400

(Updated - September 24, 2026 5:37 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy rating and a price target of $704.00.

The analyst comments "MDGL is a commercial stage company focused on discovering, developing, and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH; previously non-alcoholic steatohepatitis (NASH)). The cornerstone of the company's commercial portfolio is Rezdiffra (resmetirom), a once-daily, oral, liver-directed thyroid hormone receptor (THR)-β selective agonist which was the first approved medication for NASH patients with moderate to advanced fibrosis (F2 to F3) and has now achieved a trailing twelve month revenue

Goldman Sachs Assumes Madrigal Pharmaceuticals (MDGL) at Buy

Thu, 24 Sep 2026 05:37:21 -0400

(Updated - September 24, 2026 5:37 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy rating and a price target of $704.00.

Citi initiates Madrigal Pharmaceuticals coverage with Buy rating

Wed, 23 Sep 2026 05:04:34 -0400

(Updated - September 23, 2026 5:04 AM EDT)

Citi analyst Eric Joseph initiated coverage on Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy rating and a price target of $725,.

Joseph cited the company's drug Rezdiffra as central to his outlook, stating that it "remains underappreciated by investors." He noted that "launch performance has consistently exceeded expectations and blockbuster status is imminent, current levels continue to discount Rezdiffra's long-term opportunity."

The analyst pointed to uncertainty surrounding an ongoing Phase 3 outcomes confirmatory study, with an estimated topline readout in 2027, as a key factor in current valuations. Joseph referenced "encouraging signals from the F4c

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals adds J&J executive to its board

Wed, 12 Aug 2026 08:00:58 -0400

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its board of directors, the company announced Aug. 12, 2026.

Dr. Reed currently serves as Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, where he leads research and development across oncology, immunology, and neuroscience. He is also a member of Johnson & Johnson's Executive Committee.

Before joining Johnson & Johnson in April 2023, Dr. Reed held executive leadership positions at Sanofi and Roche, serving on their respective executive committees. He previously served as President and Chief Executive Officer of Sanford-Burnham Medical Research Institute, now

Madrigal Pharmaceuticals adds J&J executive to its board

Wed, 12 Aug 2026 08:00:58 -0400

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its board of directors, the company announced Aug. 12, 2026.

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors.

Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (“J&J”) and is a member of J&J’s Executive Committee, where he leads research and development across oncology, immunology, neuroscience and other areas of significant unmet medical need.

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,263 time-based restricted